A Study of BG-C477 in Participants With Advanced Solid Tumors
← catalyst calendarNCT06596473 · readout in 499 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
310estimated
Sites
58
Countries
Australia, China, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-03 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: BG-C477
- Drug: Tislelizumab — also filed as BGB-A317
- Drug: Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From first dose of the study drug(s) to 30 days after the last dose (up to approximately 2 years)
Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)
measured Approximately 1 year
Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-C477
measured Approximately 1 year
Phase 1b: Overall Response Rate (ORR)
measured Approximately 2 years
Phase 1b: Recommended Phase 2 Dose (RP2D) of BG-C477
measured Approximately 2 years
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed